Article information
Full text is only aviable in PDF
REFERENCES
[1]
JA Barberà, G Peces-Barba, AGN Agustí, et al.
Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 297-316
[2]
JI Jaén Díaz, C Castro Mesa, MJ Gontán García-Salamanca, F López de Castro.
Prevalencia y factores de riesgo de EPOC en fumadores y ex fumadores.
Arch Bronconeumol, 39 (2003), pp. 554-558
[4]
JL Izquierdo.
The burden of COPD in Spain: results from the confronting survey.
Respir Med, 97 (2003), pp. S61-SS9
[5]
J Escarrabill.
Costes sanitarios de la enfermedad pulmonar obstructiva crónica (EPOC).
Arch Bronconeumol, 39 (2003), pp. 435-436
[6]
JL Izquierdo, J de Miguel.
Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease.
Journal of COPD, 1 (2004), pp. 215-223
[7]
JL Izquierdo Alonso, D Jiménez de Castro.
Presente y futuro en el tratamiento de la EPOC.
Arch Bronconeumol, 37 (2001), pp. 34-81
[9]
RA Pauwels, AS Buist, PMA Calverley, CR Jenkins, SS Hurd.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[10]
AL Hansell, JA Walk, JB Soriano.
What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis.
Eur Respir J, 22 (2003), pp. 809-814
[11]
The TORCH study group.
The TORCH (Towards a Revolution in COPD Health) survival study protocol.
Eur Respir J, 24 (2004), pp. 206-210
[12]
JB Soriano, J Vestbo, NB Pride.
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.
Eur Respir J, 21 (2003), pp. 559-560
[13]
WD Kim, D Eidelman, JL Izquierdo, et al.
Centrilobular and panlobular emphysema in smokers. Two distinct morphological and functional entities.
Am Rev Respir Dis, 144 (1991), pp. 1385-1390
[14]
WQ Gan, SF Man, A Senthilselvan, et al.
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis.
Thorax, 59 (2004), pp. 574-580
[15]
EFM Wouters, EC Creutzberg, AM Schools.
Systemic effects in COPD.
Chest, 121 (2002), pp. 127S-130S
[16]
HJ Schunemann, J Dorn, BJ Grant, et al.
Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study.
Chest, 118 (2000), pp. 656-664
[17]
KM Bang, PJ Gergen, R Kramer, et al.
The effect of pulmonary impairment on all-cause mortality in a national cohort.
Chest, 103 (1993), pp. 536-540
[18]
DJ Hole, GC Watt, G Davey-Smith, et al.
Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.
BMJ, 313 (1996), pp. 711-715
[19]
R Ross.
Atherosclerosis—an inflammatory disease.
N Engl J Med, 340 (1999), pp. 115-126
[20]
G Engstrom, P Lind, B Hedblad, et al.
Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins.
Circulation, 106 (2002), pp. 2555-2560
[21]
PM Ridker, M Cushman, MJ Stampfer, et al.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
N Engl J Med, 336 (1997), pp. 973-979
[22]
J Danesh, P Whincup, M Walker, et al.
Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses.
BMJ, 321 (2000), pp. 199-204
[23]
W Koenig, H Lowel, J Baumert, et al.
C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.
Circulation, 109 (2004), pp. 1349-1353
[24]
R Arroyo-Espliguero, P Avanzas, J Cosín-Sales, et al.
C-reactive protein elevation and disease activity in patients with coronary heart disease.
Eur Heart J, 25 (2004), pp. 401-408
[25]
R Arroyo-Espliguero, P Avanzas, JC Kaski.
Enfermedad cardiovascular ateroesclerótica: la utilidad de la proteína C reactiva en la identificación de la placa vulnerable y del paciente vulnerable.
Rev Esp Cardiol, 57 (2004), pp. 375-378
[26]
E Zouridakis, P Avanzas, R Arroyo-Espliguero, et al.
Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris.
Circulation, 110 (2004), pp. 1747-1753
[27]
P Libby, PM Ridker, A Maseri.
Inflammation and atherosclerosis.
Circulation, 105 (2002), pp. 1135-1143
[28]
S Verma, S Li, M Badiwala, et al.
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein.
Circulation, 105 (2002), pp. 1890-1896
[29]
DD Sin, SF Man.
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.
Circulation, 107 (2003), pp. 1514-1519
[30]
M Dahl, A Tybjaerg-Hansen, J Vestbo, et al.
Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease.
Am J Crit Care Med, 164 (2001), pp. 1008-1011
[31]
DD Sin, P Lacy, E York, et al.
Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 170 (2004), pp. 760-765
[32]
R Arroyo-Espliguero, P Avanzas, S Jeffery, et al.
CD 14 and toll-like receptor 4: a link between infection and acute coronary events?.
Heart, 90 (2004), pp. 983-988
[33]
M Roland, A Bhowmik, RJ Sapsford, et al.
Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease.
Thorax, 56 (2001), pp. 30-35
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
